News and Trends 25 Jan 2017 Novartis Relies on Biotech to keep up its Solid Financial Performance …The company also has ongoing partnerships with biotechs such as the German Morphosys. Together, the team is currently evaluating 12 therapeutic antibody candidates for applications ranging from obesity and type… January 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Feb 2024 Japan’s ten hottest biotech companies in healthcare …regenerative route to saving the heart via stem cell therapy. The same month the company announced its collaboration with Novo Nordisk to develop its lead candidate, HS-001. In the lab,… February 27, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 18 Nov 2022 How cardioids can usher in the next generation of drug discovery …approaches use animal models and cell-based screening assays to select new drug candidates. You first start with a large number of drug candidates that are narrowed down to the best… November 18, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Mar 2023 5 hearing loss biotech companies you should know about …pathophysiology and etiology of diseases related to hearing loss, allowing it to select the best targets and mechanisms of action for drug candidates. SENS-401 is Sensorion’s clinical-stage small molecule drug… March 29, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2024 Can AI cure Alzheimer’s disease? …AI platform, Centaur Chemist, uses predictive modeling to streamline the selection of candidate compounds. This platform has already brought three AI-designed drug candidates to clinical testing, including DSP-0038 for Alzheimer’s… November 1, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 …alike. U.S.-based MBX’s $187.7 million offering will fund its lead candidate MBX 2109 – hoping to take on Yorvipath – into phase 3 studies. The IPO was following the news… November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 May 2023 5 cell therapy companies you should know about …pipeline includes candidates being investigated for the treatment of synovial sarcoma, head and neck cancer, esophageal cancer, ovarian cancer, and more. Afamitresgene autocel is the company’s first-generation TCR T-cell therapy… May 10, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023 Genoscience Pharma receives orphan drug designation for hepatocellular carcinoma drug Genoscience Pharma has announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA)… February 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2024 Eight areas where gene therapy shines …Administration (FDA) in 2023. Pfizer is also advancing giroctocogene fitelparvovec, a candidate for the same indication, and recently reported positive phase 3 data. Gene therapy for neurological disorders Neurological disorders… November 21, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Cyxone receives approval for phase 2b rheumatoid arthritis study …and multiple sclerosis. Rabeximod is a phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a phase 1 candidate drug for treatment of multiple sclerosis…. September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has… December 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies …portfolio and the option to gain rights for additional targets, up to a total of eight nanobody candidates. If Sanofi opts in for all eight candidates and they reach commercialization,… July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email